0 3 HLA HLA NNP 4 9 class class NN 10 20 I-mediated i-mediated JJ 21 30 induction induction NN 31 33 of of IN 34 38 cell cell NN 39 52 proliferation proliferation NN 53 61 involves involve VBZ 62 68 cyclin cyclin NN 69 79 E-mediated e-mediated JJ 80 92 inactivation inactivation NN 93 95 of of IN 96 98 Rb Rb NNP 99 107 function function NN 108 111 and and CC 112 121 induction induction NN 122 124 of of IN 125 128 E2F E2F NNP 129 137 activity activity NN 137 138 . . . 140 147 Chronic chronic JJ 148 157 rejection rejection NN 158 160 of of IN 161 173 transplanted transplant VBN 174 180 organs organ NNS 181 183 is be VBZ 184 194 manifested manifest VBN 195 197 as as IN 198 213 atherosclerosis atherosclerosis NN 214 216 of of IN 217 220 the the DT 221 226 blood blood NN 227 234 vessels vessel NNS 235 237 of of IN 238 241 the the DT 242 251 allograft allograft NN 251 252 . . . 253 256 HLA HLA NNP 257 262 class class NN 263 264 I i CD 265 268 Ags ag NNS 269 273 have have VBP 274 278 been be VBN 279 289 implicated implicate VBN 290 292 to to TO 293 297 play play VB 298 299 a a DT 300 305 major major JJ 306 310 role role NN 311 313 in in IN 314 318 this this DT 319 326 process process NN 326 327 , , , 328 333 since since IN 334 343 signaling signaling NN 344 347 via via IN 348 351 HLA HLA NNP 352 357 class class NN 358 359 I i CD 360 369 molecules molecule NNS 370 373 can can MD 374 380 induce induce VB 381 384 the the DT 385 398 proliferation proliferation NN 399 401 of of IN 402 408 aortic aortic JJ 409 420 endothelial endothelial JJ 421 423 as as RB 424 428 well well RB 429 431 as as IN 432 438 smooth smooth JJ 439 445 muscle muscle NN 446 451 cells cell NNS 451 452 . . . 453 455 In in IN 456 460 this this DT 461 466 study study NN 466 467 , , , 468 470 we we PRP 471 475 show show VBP 476 480 that that IN 481 484 HLA HLA NNP 485 490 class class NN 491 501 I-mediated i-mediated JJ 502 511 induction induction NN 512 514 of of IN 515 519 cell cell NN 520 533 proliferation proliferation NN 534 544 correlates correlate VBZ 545 549 with with IN 550 562 inactivation inactivation NN 563 565 of of IN 566 569 the the DT 570 572 Rb Rb NNP 573 580 protein protein NN 581 583 in in IN 584 587 the the DT 588 589 T t NN 590 594 cell cell NN 595 599 line line NN 600 606 Jurkat Jurkat NNP 607 609 as as RB 610 614 well well RB 615 617 as as IN 618 623 human human JJ 624 630 aortic aortic JJ 631 642 endothelial endothelial JJ 643 648 cells cell NNS 648 649 . . . 650 653 HLA HLA NNP 654 659 class class NN 660 670 I-mediated i-mediated JJ 671 683 inactivation inactivation NN 684 686 of of IN 687 689 Rb Rb NNP 690 693 can can MD 694 696 be be VB 697 706 inhibited inhibit VBN 707 719 specifically specifically RB 720 722 by by IN 723 735 neutralizing neutralize VBG 736 739 Abs ab NNS 740 742 to to TO 743 748 basic basic JJ 749 759 fibroblast fibroblast NN 760 766 growth growth NN 767 773 factor factor NN 774 775 ( ( ( 775 779 bFGF bFGF NNP 779 780 ) ) ) 780 781 , , , 782 792 suggesting suggest VBG 793 794 a a DT 795 799 role role NN 800 803 for for IN 804 807 FGF FGF NNP 808 817 receptors receptor NNS 818 820 in in IN 821 824 the the DT 825 834 signaling signaling NN 835 842 process process NN 842 843 . . . 844 853 Signaling signaling NN 854 861 through through IN 862 865 HLA HLA NNP 866 871 class class NN 872 873 I i CD 874 883 molecules molecule NNS 884 891 induced induce VBD 892 898 cyclin cyclin NN 899 911 E-associated e-associated JJ 912 918 kinase kinase NNP 919 927 activity activity NN 928 934 within within IN 935 936 4 4 CD 937 938 h h NN 939 941 in in IN 942 951 quiescent quiescent JJ 952 963 endothelial endothelial JJ 964 969 cells cell NNS 969 970 , , , 971 974 and and CC 975 983 appeared appear VBD 984 986 to to TO 987 994 mediate mediate VB 995 998 the the DT 999 1011 inactivation inactivation NN 1012 1014 of of IN 1015 1017 Rb Rb NNP 1017 1018 . . . 1019 1020 A a DT 1021 1025 cdk2 cdk2 NN 1026 1035 inhibitor inhibitor NN 1035 1036 , , , 1037 1047 Olomoucine Olomoucine NNP 1047 1048 , , , 1049 1051 as as RB 1052 1056 well well RB 1057 1059 as as IN 1060 1061 a a DT 1062 1079 dominant-negative dominant-negative JJ 1080 1084 cdk2 cdk2 NN 1085 1094 construct construct NN 1095 1104 prevented prevent VBD 1105 1108 HLA HLA NNP 1109 1114 class class NN 1115 1125 I-mediated i-mediated JJ 1126 1138 inactivation inactivation NN 1139 1141 of of IN 1142 1144 Rb Rb NNP 1144 1145 ; ; : 1146 1148 in in IN 1149 1157 contrast contrast NN 1157 1158 , , , 1159 1176 dominant-negative dominant-negative JJ 1177 1181 cdk4 cdk4 NN 1182 1185 and and CC 1186 1190 cdk6 cdk6 NN 1191 1201 constructs construct NNS 1202 1205 had have VBD 1206 1208 no no DT 1209 1215 effect effect NN 1215 1216 . . . 1217 1228 Furthermore furthermore RB 1228 1229 , , , 1230 1235 there there EX 1236 1239 was be VBD 1240 1242 no no DT 1243 1251 increase increase NN 1252 1254 in in IN 1255 1261 cyclin cyclin NN 1262 1274 D-associated d-associated JJ 1275 1281 kinase kinase NNP 1282 1290 activity activity NN 1291 1295 upon upon IN 1296 1299 HLA HLA NNP 1300 1305 class class NN 1306 1307 I i CD 1308 1316 ligation ligation NN 1316 1317 , , , 1318 1328 suggesting suggest VBG 1329 1333 that that IN 1334 1340 cyclin cyclin NN 1341 1352 E-dependent e-dependent JJ 1353 1359 kinase kinase NNP 1360 1368 activity activity NN 1369 1377 mediates mediate VBZ 1378 1380 Rb Rb NNP 1381 1393 inactivation inactivation NN 1393 1394 , , , 1395 1402 leading lead VBG 1403 1405 to to TO 1406 1409 E2F E2F NNP 1410 1420 activation activation NN 1421 1424 and and CC 1425 1429 cell cell NN 1430 1443 proliferation proliferation NN 1443 1444 . . .